

Potential clinical indications for a CCK₂ receptor antagonist

Malcolm Boyce¹, Katie A. Lloyd² and D. Mark Pritchard²

Address

¹Hammersmith Medicines Research (HMR)
Cumberland Avenue
London
NW10 7EW
United Kingdom

²Department of Cellular and Molecular Physiology
Institute of Translational Medicine
University of Liverpool
Crown Street
Liverpool
L69 3GE
United Kingdom

Corresponding author

D. Mark Pritchard Mark.pritchard@liv.ac.uk

An invited review for *Current Opinion in Pharmacology*

ABSTRACT

Gastrin controls gastric acid secretion and mucosal cell growth, especially of enterochromaffin-like cells, via gastrin/cholecystokinin-2 receptor (CCK₂R) binding and downstream signalling. Studies in animal models, healthy subjects and patients with gastric neuroendocrine tumours provide compelling evidence to justify developing a CCK₂R antagonist (CCK₂RA) for preventing or treating the trophic effects of hypergastrinaemia or conditions expressing CCK₂R, and with or without a proton pump inhibitor, for treating gastric acid-related conditions. Many compounds have been studied, but most have had problems with potency, selectivity for CCK₂ versus CCK₁ receptor, solubility or oral bioavailability. None has yet been marketed. Netazepide and Z-360 are currently undergoing clinical development, for treatment of gastric neuroendocrine tumours and pancreatic cancer, respectively. There are several other potential indications for a CCK₂RA and an unmet need.

INTRODUCTION

Gastrin is a peptide hormone produced by a single gene and synthesised from preprogastrin, which is processed into progastrin and amidated gastrin peptide fragments, mostly G17 and G34 [1]. All gastrins have a C-terminal amidated tetrapeptide that acts at G protein-coupled CCK₂R in the stomach and central and peripheral nervous systems. The C-terminal tetrapeptide is identical to that of another peptide hormone, cholecystokinin, which acts predominantly at CCK₁ receptors in the pancreas, gallbladder and central and peripheral nervous systems.

Food releases gastrin from G cells in the gastric antrum. Gastrin binds to CCK₂R on enterochromaffin-like (ECL) cells in the oxyntic mucosa causing them to synthesise and secrete histamine, which in turn stimulates adjacent parietal cells to secrete acid. Acid secretion is mediated by the proton pump on parietal cells via histamine H₂- and muscarinic M₃-receptors (Figure 1). Gastrin also induces proliferation, migration, differentiation and anti-apoptosis of gastric epithelial cells; regulates various genes in the gastric mucosa; and stimulates paracrine cascades, including cytokines and growth factors [2].

In this article, we describe the potential therapeutic uses of a CCK₂RA. We cite evidence from animal models, healthy subjects, and patients.

TYPES OF CCK₂RA

The discovery that asperlicin, a benzodiazepine-related natural product, had weak affinity for CCK₁ receptors led to invention of various benzodiazepine-derived CCK₂RA, such as L-36,718 (devazepide), L-365,260, CI-988, YM022, Z-360 and YF476 (netazepide), and to other classes of CCK₂RA [3]. Two new classes have recently been invented: JB95008 is a substituted imidazole [4] and JNJ-26070109 is a benzamide derivative [5]. Most CCK₂RA have had problems with potency, selectivity for the CCK₂ versus CCK₁ receptor, solubility or oral bioavailability. No CCK₂RA has yet been developed into a medicine.

CCK₂RA STUDIES IN ANIMAL MODELS

CCK₂RA have been tested in many types of animal model. JNJ-26070109 [5] and netazepide [6] caused dose-dependent inhibition of pentagastrin-stimulated acid secretion in rats and dogs. Netazepide prevented the increases in ECL-cell activity and density, oxyntic mucosal thickness, mucosal histamine decarboxylase (HDC) activity and serum pancreastatin caused by proton pump inhibitor (PPI) induced hypergastrinaemia in rats [7]. Pancreastatin is derived from chromogranin A (CgA), an ECL-cell biomarker. Netazepide not only prevented formation of ECL-cell derived gastric carcinoids accelerated by hypergastrinaemia induced by loxidine, an insurmountable histamine H₂-receptor antagonist (H₂RA), in *Mastomys* rodents, but also caused regression of formed lesions [8]. Netazepide and loxidine had synergistic inhibitory effects on gastric atrophy and cancer in *H. felis* infected transgenic hypergastrinaemic INS-GAS mice, whereas a PPI had no effect [9]. Netazepide also prevented: the inflammatory response of the gastric mucosa to *H. pylori* infection in Mongolian gerbils [10**]; hypergastrinaemia-induced lesions in mice similar to those observed in patients with Barrett's oesophagus [11,12]; and NSAID-induced gastric ulcers in rats as effectively as omeprazole [13]. YM022 [14] and JNJ-26070109 [5] prevented rebound hyper-responsiveness of acid secretion to pentagastrin after stopping omeprazole in rats. Co-administration of a CCK₂RA with an opioid improved anti-nociception and opioid tolerance in animal pain models [15].

CCK₂RA STUDIES IN HEALTHY SUBJECTS

There have been few studies of the clinical pharmacology of CCK₂RA in healthy subjects. L-365,260 produced modest and short lasting inhibition of gastrin-stimulated acid secretion [16]. CI-988 had some effect on CCK₄-induced panic symptoms [17]. Single oral doses of netazepide caused dose-dependent increases in basal and food-stimulated gastric pH for more than 24h [18], and dose-dependent inhibition of pentagastrin-induced gastric acid secretion

[19]. Repeated oral doses of netazepide caused persistent inhibition of pentagastrin-induced acid secretion [19,20**], and prevented the increase in plasma CgA resulting from rabeprazole-induced hypergastrinaemia [20**]. Netazepide suppressed acid production as effectively as rabeprazole, and the combination suppressed it more than either treatment alone [20**]. A spray-dried formulation of netazepide had linear pharmacokinetics and oral bioavailability of ~15% [18]. By comparison, bioavailability in rat and dog was 25–50% [6].

POTENTIAL CLINICAL INDICATIONS FOR A CCK₂RA

Thus, animal models and healthy volunteer studies provide compelling evidence for developing a CCK₂RA for clinical use. Potential indications are: hypergastrinaemia; acid-related conditions; *H. pylori* infection; and conditions where CCK₂R are overexpressed (Figure 2). However, to date there have been very few studies in patients.

HYPERGASTRINAEMIA-ASSOCIATED CONDITIONS

There are several causes of hypergastrinaemia, with possible consequences that may be treatable by a CCK₂RA.

1. Chronic atrophic gastritis (CAG) and Zollinger-Ellison syndrome (ZES)

CAG- and ZES hypergastrinaemia can lead to ECL-cell hyperplasia and in some cases gastric neuroendocrine tumours (NETs), called types 1 and 2, respectively [21]. Gastric NETs are rare [22], but have the potential to metastasise [21].

Netazepide once daily for 12 weeks reduced the number of tumours and size of the largest one and normalised circulating CgA in 16 patients with CAG, achlorhydria, hypergastrinaemia and multiple gastric NETs, [23,24**]. After 12 weeks off treatment, the number of tumours and size of the largest one remained unchanged but CgA increased again. Netazepide reduced mRNA abundances of CgA and HDC [24**] and reduced miR-222, which was over-expressed, in mucosal biopsies [25**]. miR-222 targets the tumour suppressor and oncogene p27^{kip1} (Figure 3). Serum gastrin did not increase further on netazepide, confirming patients had achlorhydria. Netazepide was safe and well tolerated. Guidelines recommend regular endoscopic surveillance and mapping and biopsy of type 1 and 2 NETs, and if there are concerns, polypectomy to remove the tumours or antrectomy/gastrinoma resection to remove the source of hypergastrinaemia [21]. However, tumours often regrow after polypectomy, and antrectomy carries the risk of morbidity and mortality and isn't always successful. A CCK₂RA is a potential alternative treatment for type 1 NETs, which are gastrin driven and comprise 80% of gastric NETs. Treatment should

probably be continuous otherwise tumours may regrow, even if eradicated. Progress can be monitored by CgA in blood or biomarkers in biopsies. Patients with pernicious anaemia (PA) also have a seven-fold increased risk of developing gastric adenocarcinoma [26]. A CCK₂RA might also help prevent gastric NETs and adenocarcinoma in PA patients. The acid suppressant and anti-trophic effects of a CCK₂RA also make it an ideal potential treatment for ZES patients with type 2 NETs. No trial has been reported.

2. PPI-induced hypergastrinaemia

Although PPIs are safe medicines, PPI-induced hypergastrinaemia has been reported to cause: ECL- and parietal-cell hyperplasia; fundic gland polyps; increased risk of bone fractures; rebound hyperacidity and dyspepsia after PPI withdrawal; and malignant ECL-cell tumours in case reports. A CCK₂RA should be free of those unwanted effects, and should prevent them if co-administered with a PPI.

(a). ECL-cell hyperplasia

In 1,920 patients from 16 studies of patients on long-term PPI therapy, mean gastrin concentrations increased by one to three times upper limit of normal, and ECL-cell hyperplasia increased by 8–52% [27]. There was no evidence of neoplasia in gastric biopsies, and no patient had gastric NETs or adenocarcinoma. *H. pylori* positive patients had a much higher risk of ECL-cell hyperplasia and corpus atrophy. There have been isolated case reports of gastric NETs [28] and gastric cancer [29] in patients with long-term PPI-induced hypergastrinaemia. A CCK₂RA does not cause ECL-cell hyperplasia and prevents PPI-induced ECL-cell hyperplasia in healthy subjects [20**].

(b). Fundic gland polyps

Long-term PPI therapy is associated with increased risk of fundic gland polyps [30*], so they merit a trial of co-administered CCK₂RA.

(c). Bone fractures

Long-term PPI therapy also increases the risk of bone fractures [31]. An effect of PPI-induced hypergastrinaemia on the vacuolar type H⁺-ATPase on osteoclasts that mediates acidification of intracellular organelles is a possible cause. Bone fracture risk is also increased in PA patients [32], and osteoporosis risk is increased in CAG patients [33], which excludes a direct effect of PPI on bone, because PA and CAG patients both have hypoacidity and secondary hypergastrinaemia.

H⁺/K⁺-ATPase β-subunit knock-out mice with hypergastrinaemia developed bone loss and deterioration of bone quality, which was partly prevented by netazepide [34]. Netazepide

caused hypoacidity and hypergastrinaemia in control animals, as expected, but no bone changes, suggesting hypergastrinaemia rather than hypoacidity is the mechanism. Thus, CCK₂RA co-administration might reduce the risk of fracture in PPI-treated patients.

(d). Rebound hyperacidity

Rebound hyperacidity and dyspepsia have been reported after PPI withdrawal [35]. Netazepide did not cause rebound hyperacidity [20**] and would prevent it should it occur after PPI withdrawal.

3. Mutations in KCNQ1, KCNE1 and ATP4A genes

Patients with the rare Jervell and Lange-Nielsen syndrome have hypergastrinaemia secondary to hypochlorhydria caused by mutations of *KCNQ1* or *KCNE1* genes, which are essential for acid secretion. Some patients develop ECL-cell tumours and gastric cancer [36*]. Patients with *ATP4A* gene mutation, which encodes the α -subunit of the proton pump, also have hypergastrinaemia and develop gastric NETs and adenocarcinoma [37*]. Such patients merit a CCK₂RA trial.

4. Cysteamine therapy for cystinosis

Cysteamine slows progression of cystinosis, by removing cystine from cells, but it increases serum gastrin and gastric acid, and is ulcerogenic. Some patients require PPI therapy [38]. A CCK₂RA, with or without a PPI, is a potential therapy.

ACID-RELATED CONDITIONS

CCK₂RA should be free of the unwanted effects of PPI-induced hypergastrinaemia, and if co-administered with a PPI should prevent those unwanted effects, and improve acid control [20**].

H. PYLORI INFECTION

H. pylori is a risk factor for peptic ulcer disease and gastric cancer. Netazepide completely prevented the inflammatory response of gastric mucosa to *H. pylori* in Mongolian gerbils [10**]. Therefore, a CCK₂RA with or without a PPI could be a useful addition to antibiotic regimens for *H. pylori* eradication. However, this has yet to be tested in patients.

CONDITIONS ASSOCIATED WITH CCK₂R EXPRESSION

CCK₂ receptors are expressed on cells of some patients with pancreatic cancer [39], Barrett's oesophagus [40], gastrointestinal stromal tumours [41], gastric adenocarcinoma [42], and other cancers. Therefore, a CCK₂RA may have therapeutic benefit.

1. Pancreatic adenocarcinoma

JB95008 prolonged life in a small placebo-controlled trial, but a second trial showed no difference between JB95008 and 5-fluorouracil. Development was stopped because JB95008 required intravenous infusion due to poor oral bioavailability [4]. In a placebo-controlled trial of gemcitabine with or without Z-360, there were no differences between treatments [43].

2. Barrett's oesophagus

PPI-induced hypergastrinaemia is associated with advanced oesophageal adenocarcinoma in patients with Barrett's oesophagus [44]. CCK₂RA co-administration should increase acid suppression and inhibit any trophic effect of PPI-induced hypergastrinaemia. A CCK₂RA alone might be adequate. A trial of the effect of netazepide on biomarkers in Barrett's patients is in progress [Abrams J, <https://clinicaltrials.gov>, NCT01298999].

3. Gastrointestinal stromal tumour (GIST)

GISTs are removed surgically if localised or treated with a tyrosine kinase inhibitor if metastatic, but they can 'escape'. Gastrin increases tumour volume and cell proliferation and stimulates kinase pathways in GIST xenografts, which express CCK₂ receptors [41]. A trial of a CCK₂RA is therefore justified.

4. Gastric adenocarcinoma

Many patients have raised serum gastrin. Alpha-amidated gastrins and their receptors are detectable in 80% [42]. It is not clear whether long-term PPI therapy increases the risk of gastric adenocarcinoma [30]. Patients usually present late, so a potential therapeutic effect of a CCK₂RA seems unlikely.

CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS

L-365,260 and CI-988 lacked effect in patients with panic disorder [45]. L-365,260 did not augment the analgesic effect of morphine in neuropathic pain [15], but Z-360 may have a role in pancreatic cancer pain [43,46].

CONCLUSIONS AND FUTURE WORK

The hormone gastrin regulates several essential biological processes, including gastric acid secretion, mucosal remodelling and proliferation via CCK₂ receptors. Hypergastrinaemia dysregulates those processes and contributes to development of various diseases. CCK₂RA inhibit CCK₂R receptor binding and have the potential to reduce pathological downstream signalling, particularly of ECL cells.

More is known about the role of gastrin in health and disease [1,2] since the last review in this journal [47], and there is further evidence of the malignant potential of hypergastrinaemia [36*,37*]. miR-222, which targets the tumour suppressor and oncogene p27^{kip1}, is a potential biomarker for monitoring gastrin-induced premalignant changes in the stomach. There is increasing evidence of involvement of CCK₂R in progression of Barrett's oesophagus [11,12,40,44].

Only netazepide and Z-360 are currently in clinical development in patients, for treatment of type 1 gastric NETs [23,24**] and pancreatic cancer [43,46], respectively. Ceclazepide (TR2-A) is a new benzodiazepine-derived CCK₂RA and prodrug that has advantages over netazepide in terms of selectivity, solubility and bioavailability, and is in pre-clinical development [48].

CONFLICTS OF INTEREST

MB owns HMR and the netazepide and ceclazepide patents. DMP has received HMR funding to study CCK₂RA.

HIGHLIGHTS

- Gastrin controls gastric acid secretion and mucosal cell growth via CCK₂R.
- CCK₂RA can prevent/treat consequences of hypergastrinaemia or acid-related diseases.
- CCK₂RA can eradicate type 1 NETs and reduce miR-222, which targets p27^{kip1}.
- miR-222 is a potential biomarker for gastrin-induced gastric premalignant changes.
- There are many other potential clinical indications for a CCK₂RA, and an unmet need.

Accepted manuscript

FIGURE LEGENDS

Figure 1. Control of gastric acid secretion

Figure 2. The main causes of hypergastrinaemia, conditions associated with increased CCK₂R expression, and status of CCK₂RA tested in patients.

1. Netazepide (YF476): Reduced number and size of the largest tumour and normalised CgA in patients with type-1 gastric NETs [23,24]. Still in development.
2. Z-360: No evidence of efficacy when added to gemcitabine, apart from apparent reduction in pain, in patients with pancreatic cancer [43]. Still in development.
3. JB95008: Intravenous infusion prolonged life significantly in patients with pancreatic cancer, but no difference when compared with 5-FU [4]. Development stopped because of poor oral bioavailability.
4. L-365,320: No effect in patients with panic disorder [45]. No augmentation of analgesic effect of morphine in patients with neuropathic pain [15]. Caused arrhythmias; development stopped [3]
5. CI-988: No effect in patients with panic disorder [45]. Development stopped [3].

Figure 3. A schematic diagram of the signalling pathways that are activated by CCK₂R binding. miR-222 transcription is increased via the PKC and PI3K pathways and partially via the MAPK pathway. The pri(ary)-miR-222 transcript is cleaved by the RNase II enzyme Drosha into a hairpin structure (pre-miR-222) which is transported from the nucleus to the cytoplasm via exportin-5. Pre-miR-222 is cleaved by a second RNase II enzyme, Dicer, into mature miR-222 which associates with RISC to target imperfect complementary mRNA sequences. Mature miR-222 inhibits the translation of p27^{kip1} which increases cell migration and epithelial mesenchymal transition in AGS_{GR} cells.

Reproduced with permission from [25]

REFERENCES

1. Dockray GJ, Moore A, Varro A, Pritchard DM: **Gastrin receptor pharmacology**. *Curr Gastroenterol Rep* 2012, **14**:453-459.
2. Dimaline R, Varro A: **Novel roles of gastrin**. *J Physiol (Lond)* 2014, **592**:2951-2958.
3. Herranz R: **Cholecystokinin antagonists: pharmacological and therapeutic potential**. *Med Res Rev* 2003, **23**:559-605.
4. Black JW: **Reflections on some pilot trials of gastrin receptor blockade in pancreatic cancer**. *Eur J Cancer* 2009, **45**:360-364.
5. Barrett TD, Lagaud G, Wagaman P, Freedman JM, Yan W, Andries L, Rizzolio MC, Morton MF, Shankley NP: **The cholecystokinin CCK₂ receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat**. *Br J Pharmacol* 2012, **166**:1684-1693.
6. Takinami Y, Yuki H, Nishida A, Akuzawa S, Uchida A, Takemoto Y, Ohta M, Satoh M, Semple G, Miyata K: **YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo**. *Aliment Pharmacol Ther* 1997, **11**:113-120.
7. Chen D, Zhao C-M, Norlén P, Björkqvist M, Ding X-Q, Kitano M, Håkanson R: **Effect of cholecystokinin-2 receptor blockade on rat stomach ECL cells**. *Cell Tissue Res* 2000, **299**:81-95.
8. Kidd M, Siddique Z, Drozdov I, Gustafsson B, Camp R, Black J, Boyce M, Modlin I: **The CCK₂ receptor antagonist, YF476, inhibits Mastomys ECL-cell hyperplasia and gastric carcinoid tumor development**. *Regul Pept* 2010, **162**:52-60.
9. Takaishi S, Cui G, Frederick DM, Carlson JE, Houghton J, Varro A, Dockray GJ, Ge Z, Whary MT, Rogers AB, *et al.*: **Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer**. *Gastroenterology* 2005, **128**:1965-1983.
10. **Sørdal Ø, Waldum H, Nordrum IS, Boyce M, Bergh K, Munkvold B, Qvigstad G: **The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils**. *Helicobacter* 2013, **18**:397-405.
A study in an animal model showing that the gastric mucosal inflammatory response to *H. pylori* infection is gastrin driven.
11. Quante M, Abrams JA, Lee Y, Wang TC: **Barrett esophagus: what a mouse model can teach us about human disease**. *Cell Cycle* 2012, **11**:4328-4338.
12. **Lee Y, Urbanska A, Hayakawa Y, Wang H, Au A, Luna A, Chang W, Jin G, Bhagat G, Abrams J, Friedman R, Varro A, Wang K, Boyce M, Rustgi A, Sepulveda A, Quante M, Wang TC: **Gastrin stimulates a CCK₂ receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus**. *Oncotarget* 2016 (accepted for publication)
The CCK₂R is expressed and upregulated in the cardia of patients with Barrett's

oesophagus (BO). In a mouse model of BO, netazepide inhibited proliferation and expansion of progenitor cells stimulated by PPI-induced or genetic hypergastrinaemia to give rise to metaplasia and dysplasia. The results suggest that hypergastrinaemia secondary to PPI therapy of BO may promote progression to oesophageal adenocarcinoma in patients with pre-existing oesophageal inflammation. (A 3-month, exploratory trial of the effect of netazepide on biomarkers in BO patients is in progress: clinicaltrials.gov, NCT01298999)

13. Webb D-L, Rudholm-Feldreich T, Gillberg L, Halim MA, Theodorsson E, Sanger GJ, Campbell CA, Boyce M, Näslund E, Hellström PM: **The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression.** *Naunyn Schmiedebergs Arch Pharmacol* 2013, **386**: 41-49.
14. Nishida A, Kobayashi-Uchida A, Akuzawa S, Takinami Y, Shishido T, Kamato T, Ito H, Yamano M, Yuki H, Nagakura Y: **Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression.** *Am J Physiol* 1995, **269**: G699-G705.
15. McCleane G: **Cholecystokinin antagonists: a new way to improve the analgesia from old analgesics?** *Curr Pharm Des* 2004, **10**:303-314.
16. Murphy MG, Sytnik B, Kovacs TO, Mertz H, Ewanik D, Shingo S, Lin JH, Gertz BJ, Walsh JH: **The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans.** *Clin Pharmacol Ther* 1993, **54**:533-539.
17. Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A: **Effect of CI-998 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.** *Biol Psychiatry* 1995, **38**:742-746.
18. Boyce M, David O, Darwin K, Mitchell T, Johnston A, Warrington S: **Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.** *Aliment Pharmacol Ther* 2012, **36**:181-189.
19. Boyce M, Warrington S, Black J: **Netazepide, a gastrin/CCK₂ receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.** *Br J Clin Pharmacol* 2013, **76**:689-698.
20. ****Boyce M, Downen S, Turnbull G, Berg F, Zhao CM, Chen D, Black J: Effect of netazepide, a gastrin/CCK₂ receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.** *Br J Clin Pharmacol* 2015, **79**:744-755.
A proof-of-concept study showing that a CCK₂RA suppresses gastric acid production as effectively as a proton pump inhibitor, and that the combination is more effective than either treatment alone. Furthermore, the CCK₂RA inhibits the trophic effect of hypergastrinaemia induced by the proton pump inhibitor.
21. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, Sasano H, Tomassetti P, Salazar R, Ruszniewski P: **ENETS consensus guidelines for**

the management of patients with gastroduodenal neoplasms. *Neuroendocrinology* 2012, **95**:74-87.

22. Boyce M, Thomsen L: **Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK₂ receptor antagonist.** *Scand J Gastroenterol* 2015, **50**:550-559.
23. Fossmark R, Sordal O, Jianu CS, Qvigstad G, Nordrum IS, Boyce M, Waldum HL: **Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.** *Aliment Pharmacol Ther* 2012, **36**:1067-1075.
24. **Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM: **Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.** *PLoS One* 2013, **8**:e76462.
References 23 and 24 provide evidence that a CCK₂RA might be capable of preventing or eradicating type 1 gastric tumours, which are gastrin driven.
25. **Lloyd KA, Moore AR, Parsons BN, O'Hara A, Boyce M, Dockray GJ, Varro A, Pritchard DM: **Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27^{kip1}.** *Oncotarget* 2016 (accepted for publication).
Netazepide reduced overexpressed miR-222 in the serum and gastric corpus mucosa of patients with CAG, hypergastrinaemia and gastric NETs. miR-222 increased again after stopping netazepide. Gastrin-induced miR-222 overexpression resulted in reduced expression and cytoplasmic mislocalisation of p27^{kip1}, a tumour suppressor and oncogene.
26. Vannella L, Lahner E, Osborn J, Annibale B: **Systematic review: gastric cancer incidence in pernicious anaemia.** *Aliment Pharmacol Ther* 2013, **37**:375-382.
27. Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas P: **Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology.** *Aliment Pharmacol Ther* 2015, **42**:649-663.
28. Jianu C, Fossmark R, Viset T, Qvigstad G, Sørđal Ø, Mårvik R, Waldum H: **Gastric carcinoids after long-term use of a proton pump inhibitor.** *Aliment Pharmacol Ther* 2012, **36**:644-649.
29. Jianu CS, Lange OJ, Viset T, Qvigstad G, Martinsen TC, Fougner R, Kleveland PM, Fossmark R, Hauso Ø, Waldum HL: **Gastric neuroendocrine carcinoma after long-term use of a proton pump inhibitor.** *Scand J Gastroenterol* 2012, **47**:64-67.
30. *Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD: **Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis.** *Clin Gastroenterol Hepatol* 2016. DOI: 10.1016/j.cgh.2016.05.018
Long-term use of PPIs is associated with increased risk of fundic gland polyps, and might also increase the risk of gastric cancer.

31. Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD, CaMos Research Group: **The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.** *Osteoporos Int* 2013, **24**:1161-1168.
32. Goerss JB, Kim CH, Atkinson EJ, Eastell R, O'Fallon WM, Melton LJ: **Risk of fractures in patients with pernicious anemia.** *J Bone Miner Res* 1992, **7**:573-579.
33. Kim HW, Kim Y-H, Han K, Nam GE, Kim GS, Han B-D, Lee A, Ahn JY, Ko BJ: **Atrophic gastritis: a related factor for osteoporosis in elderly women.** *PloS One* 2014, **9**:e101852.
34. Aasarød K, Ramezanzadehkoldeh M, Shabestari M, Mosti M, Stunes A, Reseland J, Beisvag V, Eriksen E, Sandvik A, Erben R *et al.* **Skeletal effects of a gastrin receptor antagonist in H⁺/K⁺ATPase beta subunit KO mice.** *J Endocrinol* 2016; **230**: 251–262.)
35. Reimer C, Søndergaard B, Hilsted L, Bytzer P: **Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.** *Gastroenterology* 2009, **137**:80-87. e81.
36. *Winbo A, Sandström O, Palmqvist R, Rydberg A: **Iron-deficiency anaemia, gastric hyperplasia, and elevated gastrin levels due to potassium channel dysfunction in the Jervell and Lange-Nielsen Syndrome.** *Cardiol Young* 2013, **23**:325-334. Evidence of the malignant potential of hypergastrinaemia.
37. *Calvete O, Reyes J, Zuñiga S, Paumard-Hernández B, Fernández V, Bujanda L, Rodriguez-Pinilla MS, Palacios J, Heine-Suñer D, Banka S *et al.*: **Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastric neuroendocrine tumour.** *Hum Mol Genet* 2015, **24**:2914-2922. Further evidence of the malignant potential of hypergastrinaemia.
38. Elmonem MA, Veys KR, Soliman NA, van Dyck M, van den Heuvel LP, Levchenko E: **Cystinosis: a review.** *Orphanet J Rare Dis* 2016, **11**:47. doi: 10.1186/s13023-016-0426-y.
39. Smith JP, Whitcomb DC, Matters GL, Brand RE, Liao J, Huang Y-J, Frazier ML: **Distribution of cholecystokinin-2 receptor genotype between patients with pancreatic cancer and controls and its impact on survival.** *Pancreas* 2015, **44**: 236-242.
40. Haigh CR, Attwood SE, Thompson DG, Jankowski JA, Kirton CM, Pritchard DM, Varro A, Dimaline R: **Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK₂ receptor.** *Gastroenterology* 2003, **124**:615-625.
41. Quattrone A, Dewaele B, Wozniak A, Bauters M, Vanspauwen V, Floris G, Schöffski P, Chibon F, Coindre JM, Sciot R: **Promoting role of cholecystokinin 2 receptor (CCK2R) in gastrointestinal stromal tumour pathogenesis.** *J Pathol* 2012, **228**: 565-574.
42. Goetze JP, Eiland S, Svendsen LB, Vainer B, Hannibal J, Rehfeld JF: **Characterization of gastrins and their receptor in solid human gastric adenocarcinomas.** *Scand J Gastroenterol* 2013, **48**:688-695.

43. Meyer T, Caplin ME, Palmer DH, Valle JW, Larvin M, Waters JS, Coxon F, Borbath I, Peeters M, Nagano E, *et al.*: **A phase Ib/IIa trial to evaluate the CCK₂ receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer.** *Eur J Cancer* 2010, **46**:526-533.
44. Wang JS, Varro A, Lightdale CJ, Lertkowitz N, Slack KN, Fingerhood ML, Tsai WY, Wang TC, Abrams JA: **Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus.** *Am J Gastroenterol* 2010, **105**: 1039-1045.
45. Rehfeld JF: **Cholecystokinin and panic disorder—three unsettled questions.** *Regul Pept* 2000, **93**:79–83.
46. Orikawa Y, Kato H, Seto K, Kobayashi N, Yoshinaga K, Hamano H, Hori Y, Meyer T, Takei M: **Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice.** *Mol Pain* 2010, **6**:72. doi: 10.1186/1744-8069-6-72.
47. Berna MJ, Tapia JA, Sancho V, Jensen RT: **Progress in developing cholecystokinin CCK/gastrin receptor ligands which have therapeutic potential.** *Curr Opin Pharmacol* 2007, **7**:583-592.
48. Boyce MJ, Thomsen L, Gilbert DA, Wood D: **Benzodiazepine derivatives as CCK₂/gastrin receptor antagonists.** Patent WO 2016/020698. 11 February 2016.

Figure 1





Figure 2



1. **Netazepide (YF476)**: Reduced number and size of the largest tumour and normalised CgA in patients with type-1 gastric NETs [23,24]. Still in development.
2. **Z-360**: No evidence of efficacy when added to gemcitabine, apart from apparent reduction in pain, in patients with pancreatic cancer [43]. Still in development.
3. **JB95008**: Intravenous infusion prolonged life significantly in patients with pancreatic cancer, but no difference when compared with 5-FU [4]. Development stopped because of poor oral bioavailability.
4. **L-365,320**: No effect in patients with panic disorder [45], no augmentation of analgesic effect of morphine in patients with neuropathic pain [15]. Caused arrhythmias; development stopped [3].
5. **CI-988**: No effect in patients with panic disorder [45]. Development stopped [3].

Figure 3

